Business Description

Description
DNIB Unwind Inc, formerly BIND Therapeutics Inc was incorporated under the laws of the state of Delaware on May 19, 2006 under the name BIND Biosciences, Inc., and changed its name to BIND Therapeutics, Inc in April 2013. The Company is a clinical-stage nanomedicine platform company developing a pipeline of Accurins, its novel targeted therapeutics designed to result in superior patient outcomes by increasing the concentration and duration of therapeutic payloads at disease sites while reducing exposure to healthy tissue. The Company's wholly owned, lead drug candidate, BIND-014, is a prostate-specific membrane antigen (PSMA) -targeted Accurin that contains docetaxel, a clinically-validated and widely-used cancer chemotherapy drug, as the therapeutic payload. PSMA is a clinically-validated tumor marker expressed on prostate cancer cells and the blood vessels of many types of non-prostate solid tumors, including non-small cell lung cancer, or NSCLC. BIND-014 is currently in development for the treatment of NSCLC patients with KRAS mutations or squamous histology. It has a pilot manufacturing facility at its Cambridge location where it conducts process development, scale-up activities and assembles the manufacturing equipment in a non-GMP environment. The Company faces competition from other nanomedicine platforms developing targeted therapies, including platforms focused on albumin nanoparticles, liposomes and polymeric nanoparticles. BIND-014 and any other drug candidates that the Company develops must be approved by the FDA before it may be legally marketed in the United States and by the appropriate foreign regulatory agency before it may be legally marketed in foreign countries.

Financial Strength

Name Current Vs Industry Vs History

Growth Rank

Name Current Vs Industry Vs History

Momentum Rank

Name Current Vs Industry Vs History
6-1 Month Momentum % -81.53
12-1 Month Momentum % -93.58

Liquidity Ratio

Name Current Vs Industry Vs History

Dividend & Buy Back

Name Current Vs Industry Vs History

Profitability Rank

Name Current Vs Industry Vs History
FCF Margin % -266.6

GF Value Rank

Name Current Vs Industry Vs History

Financials

BINDQ's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with OTCPK:BINDQ

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

DNIB Unwind Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 14.849
EPS (TTM) ($) -1.9
Beta 0
Volatility % 0
14-Day RSI 0
14-Day ATR ($) 0
20-Day SMA ($) 0
12-1 Month Momentum % -93.58
52-Week Range ($) 0.11 - 5.24
Shares Outstanding (Mil) 20.89

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 0
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

DNIB Unwind Inc Filings

Filing Date Document Date Form
No Filing Data

DNIB Unwind Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

DNIB Unwind Inc Frequently Asked Questions

What is DNIB Unwind Inc(BINDQ)'s stock price today?
The current price of BINDQ is $0.14. The 52 week high of BINDQ is $5.24 and 52 week low is $0.11.
When is next earnings date of DNIB Unwind Inc(BINDQ)?
The next earnings date of DNIB Unwind Inc(BINDQ) is .
Does DNIB Unwind Inc(BINDQ) pay dividends? If so, how much?
DNIB Unwind Inc(BINDQ) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1